Guhan Pharmaceutical Group Co., Ltd.
000590.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.2B
Close$
$-0.92
110.4% downside
Current Fair Value
110.4% downsideOvervalued by 110.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.20 Billion |
|---|---|
| Enterprise Value | $2.24 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.21 |
| Beta | 0.22 |
| Outstanding Shares | 239,471,267 |
Return
| Return on Equity | -9.07% |
|---|---|
| Return on Assets | -5.58% |
| Return on Invested Capital | -7.06% |
Valuation & Multiples
| P/E Ratio | -45.27 |
|---|---|
| PEG | -5.71 |
| Price to Sales | 8.84 |
| Price to Book Ratio | 4.42 |
| Enterprise Value to Revenue | 6.81 |
| Enterprise Value to EBIT | -46.8 |
| Enterprise Value to Net Income | -47 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.28 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Guhan Pharmaceutical Group Co., Ltd.
1,064 employees
CEO: Xue Feng Guhan Pharmaceutical Group Co., Ltd., along with its various subsidiaries, operates as a prominent Chinese pharmaceutical enterprise. The company focuses on the production and distribution of traditional Chinese medicine (TCM), conventio...